NIH deploys Picodya’s B-Matrix in vitro diagnostics platform to detect global viral threats
Picodya announced the deployment of its B-Matrix technology in National Institutes of Health (NIH) laboratories.
This deployment may enable large-scale global serologic surveillance with real-time monitoring of the immune status of human populations and detection of viral outbreaks, which could further the PREMISE goal of establishing a preemptive repository of candidate immunobiological countermeasures.
Picodya's B-Matrix platform is one of the first xPOCT IVD solutions that performs both molecular and immunoassays from many body fluids on a single platform. The hybrid and scalable technology aims to deliver lab-comparable test results in a single patient encounter, considerably shortening the diagnostic timeline.
PREMISE partnered with Picodya during initial phases of development to install the B-Matrix technology at NIAID Vaccine Research Center’s (VRC) laboratories to detect reactivity to multiple potential pandemic threats. The program was presented by Daniel Douek, MD, Ph.D., to the White House Office of Science and Technology Policy in September 2021.
